{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:43:59Z","timestamp":1775609039019,"version":"3.50.1"},"reference-count":25,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Interleukin (IL)-4, IL-13, IL-17, IL-22 and IL-3 are overexpressed in prurigo nodularis (PN). They mediate their action via the Janus Kinase (JAK) Signal transducer and activator of transcription (STAT) pathway.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>Our aim was to study the expression of tissue STAT1, STAT3, and STAT6, as well as the efficacy of the JAK-STAT inhibitor, tofacitinib, in PN.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A prospective study was conducted in a tertiary care hospital. Patients with PN were recruited after excluding secondary causes. Pruritus was graded using Pruritus Grading System Score (PGSS). All cases underwent histological assessment using immunohistochemical markers for STAT1, STAT3, and STAT6 in both lesional and perilesional skin. Tofacitinib was initiated at a dose of 5 mg twice daily or 11 mg once daily and then tapered to a maintenance dose. The final PGSS at the time of data evaluation, as well as the occurrence of remissions and relapses, was assessed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The majority of the 17 patients included in the study had moderate to severe disease. Immunohistochemical analysis revealed marked tissue expression of STAT6 in 13 and STAT3 in 10 patients, while STAT1 expression was seen in only 4 patients [p &lt; 0.05], suggesting a Th2\/Th17 tissue response. The mean onset of action of tofacitinib was 11.2 \u00b1 6.44 days and the mean duration of treatment was 5.6 \u00b1 2.2 months. A significant reduction in PGSS was noted after treatment (66.1%, P value 0.0004). Fourteen of the patients maintained remission on low-dose therapy (5 mg OD or A\/D) while one patient experienced a relapse. No serious adverse effects were noted.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Limitation<\/jats:title>\n<jats:p>We could not study the tissue cytokines and the expression of STATs after achieving clinical response on oral tofacitinib.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The efficacy of tofacitinib in PN is based on its inhibitory effect on Th2 and Th17 cytokines, which is dependent on STAT6 and STAT3.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_1017_2024","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:03:39Z","timestamp":1737356619000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib \u2013 A prospective single-arm investigational study"],"prefix":"10.25259","volume":"0","author":[{"given":"Kabir","family":"Sardana","sequence":"first","affiliation":[{"name":"Department of Dermatology, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinu Rose","family":"Mathachan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aster DM Healthcare, Discovery Gardens, Dubai, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aishwarya","family":"Muddebihal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diksha","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venkateshwara Institute of Medical Sciences, Amroha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Department of Pathology, Atal Bihari Vajpayee Institute of Medical Sciences & Dr. Ram Manohar Lohia Hospital, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"10.25259\/IJDVL_1017_2024\/ref-1","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/ijd.16834","article-title":"A case-control study addressing the population of epidermal and dermal inflammatory infiltrate including neural milieu in primary prurigo nodularis using S-100 and toluidine blue stain and its therapeutic implications","volume":"62","author":"Agrawal","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_1017_2024\/ref-2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.25259\/IJDVL_1017_2024\/ref-3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-023-00746-x","article-title":"Strategies to therapeutically modulate cytokine action","volume":"22","author":"Leonard","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.25259\/IJDVL_1017_2024\/ref-4","doi-asserted-by":"publisher","first-page":"1301817","DOI":"10.3389\/fimmu.2023.1301817","article-title":"Molecular mechanisms of pruritus in prurigo nodularis","volume":"14","author":"Shao","year":"2023","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_1017_2024\/ref-5","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1365-2133.2011.10498.x","article-title":"Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis","volume":"165","author":"Fukushi","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_1017_2024\/ref-6","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1111\/jocd.14709","article-title":"A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications","volume":"21","author":"Agrawal","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"10.25259\/IJDVL_1017_2024\/ref-7","first-page":"39","article-title":"Using pruritus grading system for measurement of pruritus in patients with diseases associated with itch","volume":"46","author":"Al-Qarqaz","year":"2012","journal-title":"J Med J"},{"key":"10.25259\/IJDVL_1017_2024\/ref-8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1126\/science.8140422","article-title":"Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6","volume":"264","author":"Zhong","year":"1994","journal-title":"Science"},{"key":"10.25259\/IJDVL_1017_2024\/ref-9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.25259\/IJDVL_1017_2024\/ref-10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/hmg\/11.6.613","article-title":"STAT6 as an asthma candidate gene: Polymorphism-screening, association and haplotype analysis in a Caucasian sib-pair study","volume":"11","author":"Duetsch","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.25259\/IJDVL_1017_2024\/ref-11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/380630a0","article-title":"Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene","volume":"380","author":"Shimoda","year":"1996","journal-title":"Nature"},{"key":"10.25259\/IJDVL_1017_2024\/ref-12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/s1074-7613(00)80439-2","article-title":"Stat6 is required for mediating responses to IL-4 and for development of Th2 cells","volume":"4","author":"Kaplan","year":"1996","journal-title":"Immunity"},{"key":"10.25259\/IJDVL_1017_2024\/ref-13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2340\/00015555-3086","article-title":"Antipruritic effects of janus kinase inhibitor tofacitinib in a mouse model of psoriasis","volume":"99","author":"Hashimoto","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_1017_2024\/ref-14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40265-021-01521-1","article-title":"IL-31 inhibition as a therapeutic approach for the management of chronic pruritic dermatoses","volume":"81","author":"Roh","year":"2021","journal-title":"Drugs"},{"key":"10.25259\/IJDVL_1017_2024\/ref-15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: A new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_1017_2024\/ref-16","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","article-title":"Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis","volume":"12","author":"Kuzumi","year":"2021","journal-title":"Nat Commun"},{"key":"10.25259\/IJDVL_1017_2024\/ref-17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jid.2019.08.438","article-title":"IL-17A Induces endothelin-1 expression through p38 pathway in prurigo nodularis","volume":"140","author":"Wong","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_1017_2024\/ref-18","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.jid.2021.02.749","article-title":"Prurigo nodularis is characterized by systemic and cutaneous t helper 22 immune polarization","volume":"141","author":"Belzberg","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_1017_2024\/ref-19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jaci.2023.04.019","article-title":"Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis","volume":"152","author":"Alkon","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_1017_2024\/ref-20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jaci.2023.07.005","article-title":"Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab","volume":"153","author":"Ma","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_1017_2024\/ref-21","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jaci.2021.10.004","article-title":"Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab","volume":"149","author":"Tsoi","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_1017_2024\/ref-22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/B978-0-7020-6896-6.00009-0","article-title":"Cytokine and cytokine receptors","volume-title":"Clinical Immunology: Principles and Practice","author":"O\u2019Shea","year":"2019","edition":"5th ed"},{"key":"10.25259\/IJDVL_1017_2024\/ref-23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25259\/ijdvl_362_2023","article-title":"Treatment of recalcitrant paediatric prurigo nodularis with tofacitinib, an exquisite example of bench-to-bedside translation of JAK-STAT expression","author":"Sardana","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_1017_2024\/ref-24","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_1017_2024\/ref-25","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/bjd\/ljae052","article-title":"Prurigo nodularis: New insights into pathogenesis and novel therapeutics","volume":"190","author":"Liao","year":"2024","journal-title":"Br J Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/translating-tissue-expression-of-stat-1-3-and-6-in-prurigo-nodularis-to-clinical-efficacy-of-oral-tofacitinib-a-prospective-single-arm-investigational-study\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/translating-tissue-expression-of-stat-1-3-and-6-in-prurigo-nodularis-to-clinical-efficacy-of-oral-tofacitinib-a-prospective-single-arm-investigational-study\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:03:41Z","timestamp":1737356621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/translating-tissue-expression-of-stat-1-3-and-6-in-prurigo-nodularis-to-clinical-efficacy-of-oral-tofacitinib-a-prospective-single-arm-investigational-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":25,"alternative-id":["10.25259\/IJDVL_1017_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_1017_2024","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"article-number":"1"}}